Slide 1: Building the Premier Women's Health Company
Building the Premier Women’s Health Company 2Q 2021 Earnings August 4, 2021
Slide 2: Forward-Looking Statements
Forward-Looking Statements FOR INVESTOR PRESENTATION PURPOSES ONLY. 2
Slide 3: Summary of Q2 Performance
Summary of Q2 Performance Overall Revenue and Unit Growth Quarter over Quarter while Navigating Covid-19 OVERALL ▪ Revenue increase of 17% 2Q21 vs 1Q21 ANNOVERA ▪ 17% TRX Growth QoQ with number of providers writing slightly increasing, as well as average units per prescriber increasing ▪ Stable Net
Slide 4: 2Q21 Financial Overview
2Q21 Financial Overview FOR INVESTOR PRESENTATION PURPOSES ONLY. 4
Slide 5: Quarterly Net Revenue Trends
Quarterly Net Revenue Trends Quarterly Net Product Revenue $24 $23.0 2Q21 Highlights $22 ▪ Total net product revenue increased 17% 2Q21 $19.6 $20 vs 1Q21 $18 ▪ Total net product revenue increased 115% 2Q21 $16 vs 2Q20 Millions $14 $12 $10.7 ▪ Net revenue per unit for ANNOVERA remained $10 steady at
Slide 6: Financial Results: Comparison 2Q 2021 to 1Q 2021 and 2Q 2020
Financial Results: Comparison 2Q 2021 to 1Q 2021 and 2Q 2020 Comparison of Key Financial Statement Items [in 1,000’s] ▪ Net product revenue of $23.0M was an increase of 2Q21 1Q21 2Q20 $12.3M compared to 2Q20 Balance Sheet(1) Cash $111,424 $137,617 $113,839 ▪ Gross margin of 82% increased from 59% in
Slide 7: ANNOVERA: Unique Opportunity to Create a New Segment within Birth Control
ANNOVERA: Unique Opportunity to Create a New Segment within Birth Control FOR INVESTOR PRESENTATION PURPOSES ONLY. 7
Slide 8: ANNOVERA TRX: Continued Growth Quarter over Quarter
ANNOVERA TRX: Continued Growth Quarter over Quarter ANNOVERA Quarterly TRx 2Q21 Key Metrics ▪ 202% YoY and 17% QoQ TRX growth 7,299 ▪ Net revenue per unit stable at $1,157(1) 7,000 6,239 ▪ Refill rates remain steady at ~50% 5,950 6,000 Growth Drivers 5,160 5,000 ▪ Growing access to our most importan
Slide 9: ANNOVERA Writers Steady with Depth of Writing Continuing to Grow
ANNOVERA Writers Steady with Depth of Writing Continuing to Grow 8,000 Number of Prescribers Key Takeaways 7,299 7,000 Units of ANNOVERA ▪ Despite COVID-19, new prescribers 6,239 increased slightly to ~3,200 6,000 5,950 ▪ Average number of prescriptions per 5,160 5,000 prescriber increased 10% from
Slide 10: ANNOVERA Creating a New Procedure Free Long-Acting Segment
ANNOVERA Creating a New Procedure Free Long-Acting Segment New messaging focuses on long-acting procedure free alternative to IUD is attracting previous IUD users Q4 2020 YTD 2021 Oral Contraception 22% 24% NuvaRing & Generics 53% 44% Injection/Patch 13% 12% IUD/Implant 8% 14% New to Birth Control 5
Slide 11: ANNOVERA Near Term Potential Growth Catalysts
ANNOVERA Near Term Potential Growth Catalysts Environment Payor Provider Consumer ▪ ACA being upheld ▪ 57% of Unrestricted ▪ Increased access to top ▪ Continued focus on the Coverage providers with opening growing telemedicine ▪ Language in house of country channel appropriations ▪ CMS recommended i
Slide 12: IMVEXXY: Fastest Growing Branded Product in Vulvar and Vaginal Atrophy Category
IMVEXXY: Fastest Growing Branded Product in Vulvar and Vaginal Atrophy Category FOR INVESTOR FOR PRESENTATION INVESTOR PRESENTATION PURPOSES PURPOSES ONLY. ONLY. 12
Slide 13: IMVEXXY Performance Drivers
IMVEXXY Performance Drivers IMVEXXYIMVEXXY Quarterly Performance 2Q21 Key Metrics Weekly NRx ▪ IMVEXXY TRX outpaced the VVA market with TRX increasing 8% 2Q21 vs TRx 1Q21 ▪ Net revenue per unit improved to $64 120 117 ▪ 4th quarter in a row growing net revenue per unit for IMVEXXY ▪ ~2% increase in
Slide 14: IMVEXXY Net Price Per Unit Build Shows Improvement Post Cash Pay Change
COMPANY OVERVIEW KEY PRODUCTS FINANCIALS IMVEXXY Net Price Per Unit Build Shows Improvement Post Cash Pay Change Jan 1st Cash Pay Changed to $75 $70 $65 $64 $61 ▪ 56% improvement in net price per unit for $60 2Q21 compared to 2Q20 $55 $54 $51 ▪ 5% improvement in $50 net price per unit for 2Q21 compa
Slide 15: IMVEXXY Near Term Potential Growth Catalysts
IMVEXXY Near Term Potential Growth Catalysts Payor Provider Consumer ▪ 61% commercial coverage ▪ Opportunity for increased with 8 of 9 top commercial access to top providers with ▪ Recent launch of new plans secured opening of country telemedicine provider for increased access to ▪ Top 5 payor that
Slide 16: BIJUVA: First and Only FDA-Approved Bio-Identical Solution in VMS Market
BIJUVA: First and Only FDA-Approved Bio-Identical Solution in Vasomotor Symptoms (VMS) Market FOR INVESTOR FOR PRESENTATION INVESTOR PRESENTATION PURPOSES PURPOSES ONLY. ONLY. 16
Slide 17: BIJUVA Volume Increased YoY with Limited Focus
BIJUVA Volume Increased YoY with Limited Focus BIJUVA Quarterly Performance BIJUVA 2Q21 Key Metrics TRx ▪ BIJUVA TRX increased 3.5% 2Q21 vs 1Q21 33 ▪ ~4% increase in prescribers writing a prescription in 2Q21 31.9 compared to 1Q21 (~5.1K vs ~4.9K) 31 30.8 ▪ Net revenue per unit remained steady at $6
Slide 18: Key Takeaways
Key Takeaways ▪ Strong quarter for the portfolio with 115% revenue growth 2Q21 vs 2Q20 and sequential quarter growth of 17% ▪ Cash used in operating activities decreased to $26.5MM ▪ Expect accelerated prescription trend to continue due to improved access online and in person ▪ Positive growth trend
Slide 19: vitaCare prescription services benefits
Simplifies the process for obtaining a prescription, improving continuity of care and better patient outcomes Allows for visibility over the patient experience Provides transparency and detailed data insights PROPRIETARY AND CONFIDENTIAL 19
Slide 20: Q&A
Q&A FOR INVESTOR PRESENTATION PURPOSES ONLY. 20
Slide 21: Appendix
Appendix FOR INVESTOR PRESENTATION PURPOSES ONLY. 21
Slide 22: Quarterly Net Revenue Trends
Quarterly Net Revenue Trends Quarterly Net Product Revenue $24 $23.0 2Q21 Highlights $22 $19.6 ▪ Total net product revenue increased 115% 2Q21 vs 2Q20 $20 $18 ANNOVERA: $9.6 ▪ ANNOVERA net revenue increased 421% $16 ANNOVERA: $8.8 Millions $14 BIJUVA: $2.2 ▪ IMVEXXY net revenue increased 93% $12 $10
Slide 23: NRx Trend of Recently Launched Mass Market Product Volumes
NRx Trend of Recently Launched Mass Market Product Volumes COVID’s impact on recently launched brands Brand Name Indication June-21 May-21 April-21 March-21 February-21 January-21 ANNOVERA Contraception - TXMD 2,391 2,094 2,140 2,145 1,724 1,770 PHEXXI Contraception 4,406 2,987 3,891 4,282 2,446 1,8
Slide 24: Payor Status and Update
Payor Status and Update Coverage July 1st, 2021 Access Summary: ▪ Annovera: Commercial 57% UR, 66%(1) ▪ 6 of 9 top Commercial plans secured ▪ Medi-Cal expansion in January 2022 Medicaid 56%(2) ▪ Recommended for J-Code approval by CMS to be implemented as early as Q421 Department of On Formulary Defe
Slide 25: Payor Progress: Maintained All Major Commercial Payors
COMPANY OVERVIEW KEY PRODUCTS FINANCIALS Payor Progress: Maintained All Major Commercial Payors Access Summary: IMVEXXY Coverage ▪ Have 8 or the 9 top Commercial plans July 1st, 2021 ▪ Preferred Contract with one top 5 Payor Commercial 61% Part D 40%(1) Source: MMIT as of July 1st 2021. Note: (1) In
Slide 26: Recognition is Growing of ANNOVERA's Unique Position in the Marketplace
Recognition is Growing of ANNOVERA’s Unique Position in the Marketplace Annovera is being seen as a Long-Acting Option which is driving intent to write more Rings Provider AWARENESS OF ANNOVERA ANNOVERA is GROWING in association as PROVIDERS EXPECT TO WRITE MORE RINGS, HIGHER than other new birth co